Asia300

Cipla Ltd.

India

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
Sep 21, 2017
Prev close: 591.45
Sep 21, 2017
Market cap:
Market cap(USD):
475,931.15M
7,344.61M
Shares: 804.68M

Currency in INR

Company profile

Market(Ticker): BOM(500087)
Sector:
Industry:
Health Technology
Pharmaceuticals: Other
Full time employees: 32,374

Business summary

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company operates through two segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. It also includes CipTec, a division within the company, which is to establish a strong specialty business in U.S. with significant focus on business development and evaluating investment opportunities. Its products portfolio includes prescription drugs, animal healthcare products, bulk drugs, OTC products, agrochemicals and technology. Cipla was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Company background

Cipla is a major Indian generic drugmaker, competing for second place in the industry in India in terms of the size of its business. It has been doing business in 170 countries and has over 30 production bases. It is a long-established company compared with other Indian leading generic drugmakers. The predecessor of Cipla was founded by K. A. Hamied in 1935, long before India's independence in 1947. It is said that Mahatma Gandhi visited Cipla and asked Hamied to supply medicines that were desperately needed in India at the time. During World War II, Hamied crisscrossed the country to supply medicines that were in short supply due to stagnant imports.

As a trailblazer in India's pharmaceutical industry, Cipla has been busily expanding its business in Africa and other emerging economies. In particular, it is well-known for its low-cost HIV drug. In 2013, it turned a South African company it did business with into a wholly owned subsidiary.

K. A. Hamied's son Yusuf, who earned a doctorate in organic chemistry from the University of Cambridge, took over the company in 1972 and has been serving as the chairman. The founding family owns nearly 40% of the shares in the company.

In the news

Financial highlights

Mar 2017

  • Local currency
  • US Dollar
Revenue 142,298.1M
Gross profit 48,235.8M
Operating income 16,856.8M
Income before tax 12,221.7M
Net income 10,063.9M
EBITDA 25,571.4M
Diluted EPS 12.5
Dividends per share 2
Total assets 209,700.5M
Total liabilities 79,923.5M
Total equity 125,254.2M
Operating cash flow 22,350.6M

Currency in INR

Revenue 2,122.04M
Gross profit 719.32M
Operating income 251.37M
Income before tax 182.25M
Net income 150.07M
EBITDA 381.33M
Diluted EPS 0.18
Dividends per share 0.02
Total assets 3,229.39M
Total liabilities 1,230.82M
Total equity 1,928.91M
Operating cash flow 333.30M

Currency in USD

Valuation measures

Mar 2017

PER 47.30
ROA 4.78%
ROE 8.37%
Operating margin 11.84%
Profit margin 7.07%

Key executive

  • Chief Executive Officer, MD & Director: Umang Vohra
  • Global Chief Financial Officer: Kedar Upadhye
  • Secretary & Compliance Officer: Rajendra Chopra
  • Executive Vice Chairman: Samina Vaziralli
  • Chief Internal Auditor: Deepak Viegas

Share holders

  • HAMIED YUSUF KHWAJA(20.7%)
  • AHMED SOPHIE(5.7%)
  • First State Investment Management (UK) Ltd.(5.6%)
  • Life Insurance Corp. of India(5.4%)
  • ICICI Prudential Asset Management Co. Ltd.(4.5%)
  • HAMIED MUSTAFA KHWAJA(3.9%)
  • VAZIRALLI SAMINA(2.2%)
  • HDFC Asset Management Co. Ltd.(2.1%)
  • Norges Bank Investment Management(1.7%)
  • The Vanguard Group, Inc.(1.4%)

Address

  • Website: http://www.cipla.com
  • Address: Mumbai Central, Mumbai, 400 008, India
  • Phone: +91.22.23082891

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.